TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00080093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual feedback and specially-tailored manuals
Description: Individual feedback and specially-tailored manuals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General HIV information feedback and the best-available information
Description: General HIV information feedback and the best-available information
Study: NCT06031038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TECCU Software
Description: patient monitoring by software application
Study: NCT03835429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
Study: NCT04026659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise
Description: A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
Study: NCT00098501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pelitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given PO
Study: NCT01372423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mcg capsules
Study: NCT03439423

Intervention type: RADIATION
Intervention: CT with contrast agent

Intervention type: DIAGNOSTIC_TEST
Intervention: MR without contrast agent
Description: on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)

Intervention type: DIAGNOSTIC_TEST
Intervention: Color-Doppler Ultrasound

Intervention type: OTHER
Intervention: Questionnaire
Description: regarding their perception of examinations
Study: NCT02533141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry (LDV)
Description: Measurement of red blood cell velocity in retinal vessels

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Velocimetry (LDV)
Description: Measurement of red blood cell velocity in retinal vessels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 4 weeks
Study: NCT00961181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Balloon
Description: Percutaneous coronary intervention with paclitaxel releasing balloon
Study: NCT03295396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
Study: NCT04082234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnering to Achieve School Success (PASS)
Description: Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
Study: NCT01122160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole 20.6 mg tablet with berries (blackberries + strawberries)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo with berries (blackberries + strawberries)
Study: NCT02345187

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation
Description: The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified isocaloric beverage powder
Description: The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
Study: NCT04375332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARPOON™ Beating Heart Mitral Valve Repair System
Description: Repair of the chordae tendinae in the mitral valve.
Study: NCT01606709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH agonist 1mg one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: 5,000 IU one dose
Study: NCT01512134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation Device
Description: Deep brain stimulation surgery
Study: NCT03837210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pylorin
Description: Poly Herbal formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylorin
Description: Poly Herbal formulation
Study: NCT00215137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( sugar pill)
Description: Placebo Comparator in double.blind phase.
Study: NCT00283088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
Study: NCT02113345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory Cognitive Intervention
Description: Metamemory Cognitive Intervention
Study: NCT00969709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily for 8 weeks.
Study: NCT01558401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
Study: NCT02980731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
Study: NCT01140698

Intervention type: OTHER
Intervention: Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge
Description: Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
Study: NCT03143621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Brewed, caffeinated coffee, 100 cc's each dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Tap water heated to same temperature as coffee
Study: NCT02807662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Seeking Safety Intervention
Description: Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
Study: NCT00591370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: One group treatment study
Study: NCT04068766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% bupivacaine
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT00833261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel
Study: NCT02474485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVS Absorb implantation.
Description: Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEB Sequent Please inflation.
Description: Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control coronary angiography.
Description: Control coronary angiography will be performed at 9 month follow-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control coronary angiography.
Description: Control coronary angiography will be performed at 9 month follow-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT visualization.
Description: OCT visualization will be performed during index procedure and at 9 month follow-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT visualization.
Description: OCT visualization will be performed during index procedure and at 9 month follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical observation.
Description: Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical observation.
Description: Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
Study: NCT03975777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LO
Description: Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LO
Description: Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HI
Description: Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HI
Description: Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)
Study: NCT03918499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-based Biologic Agent IRX-2
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04084717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.
Study: NCT03318588

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Pars plana vitrectomy

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Pars plana vitrectomy
Study: NCT00524277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2 peptide + GM-CSF vaccine
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF (sargramostim)
Description: GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF vaccine
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF (sargramostim)
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations
Study: NCT02813889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmarToyGym
Description: We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture.
Study: NCT00301795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01119469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy (CT or ET)
Description: weekly 50-minute sessions for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy (CT or ET)
Description: weekly 50-minute sessions for 12 weeks
Study: NCT03832348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan imaging
Description: 3 PET scans will be performed after each 3 first infusions of Pembrolizumab
Study: NCT01913951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin
Description: Given IV over 10 minutes on Day 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV over 15 minutes on days 1-7
Study: NCT04452630

Intervention type: OTHER
Intervention: Infectious Disease and Cardiology Clinical Consultations
Description: Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
Study: NCT02071966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
Study: NCT03487731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (hMSCs)
Description: A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (hMSCs)
Description: A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.